October 06, 2022 (Thrusday) – Day 1

1.30 PM – 6.00 PM

Opening Remarks

7:00 PM onwards

Industry Sponsored Dinner Symposium

October 07, 2022 (Friday) – Day 2

09:00 AM – 09:15 AM

Opening Remarks

09:20 AM – 11:20 AM

Session 1

Presidential Symposium – Joint Session of ASTCT/EBMT/APBMT/WBMT

09:20 AM – 09:50 AM

Activity and Regulation of Cellular Therapies in North America
Miguel Perales, New York

09:50 AM – 10:20 AM

Activity and Regulation of Cellular Therapies in Europetreatment
Anna Sureda, Bracelona

10:20 AM -10:50 AM

Activity and Regulation of Cellular Therapies in Asia Pacific Region
Shinichiro Okamoto, Tokyo

10:50 AM – 11:20 AM

Global Trends in Cellular Therapy and its integration with HSCT- WBMT Perspective
Dietger Niederwieser,Leipzig

11:20 AM -12:00 PM

Plenary Session

Clinical Aspects of TIM-3 in myeloid malignacies – Its relevance in cellular therapy
Yoshikane Kikushige, Fukuoka

12:00 PM- 1:00 PM

Industry Sponsored Dinner Symposium

01:00 PM – 03:00 PM

Session 2 & 3

Acute Leukemia

Pediatric Session

01:00 PM – 01:30 PM

AML-CR1 Allo-HSCT in the era of genomics
Yasuhito Nannya, Kyoto

Haplo-idential transplant in Thalassemia Major
Current Status
Usanarat Anurathapan, Nakhon

01:30 PM – 02:00 PM

Prophylactic/Pre-emptive Strategies in AML post allo transplant. What's relevant in 2022?
Xiao Dong Mo,Beijing

HSCT in Primary HLH
Amir Hamidieh, Tehran

02:00 PM – 02:30 PM

ALL-CR1 Allo-HSCT in 2022: Who should get it?
David Marks,Bristol

Gene Therapy or HSCT in Storage Disorders
Joanne Kurtzberg, Durham

02:30 PM – 03:00 PM

Bridge to HSCT for relapsed ALL
Peihua Peggy Lu, Beijing

Upfront Haplo transplant for Aplastic anemias – Are we justified ?
Carmen Bonfim,Curitiba

03:00 PM- 03:30 PM

BREAK

03:30 PM- 05:30 PM

Session 4 & 5

Lymphoma/Myeloma

Pediatric Sessions

03:30 PM- 04:00 PM

Managing Post transplant relapses for Multiple Myeloma

Chandramouli Nagarajan, Singapore

ALL – Optimising conditioning for children
Christina Peters , Vienna

04:00 PM- 04:30 PM

Checkpoint Inhibitors or allogeneic transplant in refractory HD

Young Rok Do, Daegu

Cellular Therapy in metastatic neuroblastoma
Giuseppe Barone, London (TBC)

04:30 PM- 05:00 PM

Optimising choices of salvage therapies in DLBCL
TBC

Late effects post transplant in children and its management

Revathi Raj, Chennai

05:00 PM- 05:30 PM

Auto or allo transplant in PTCL
Jong Ho Won, Seoul

Transplantation in Sicle cell Disease- when and how?
Selim Corbacioglu, Bavaria

05:30 PM- 07:00 PM

Poster Session

7:00 PM onwards

Industry Sponsored Dinner Symposium

October 8 2022 (Saturday) – Day 3

08:00 AM-09:30 AM

APBMT Business Meeting

09:30 AM- 10:10 AM

Plenary Session

Cellular therapy Beyond B Cell Malignacies-

He Huang , Hangzhou

10:10 AM- 12:10 PM

Session 6 & 7

Immunology of Transplantation / GVHD

Infections

10:10 AM- 10:40 AM

Non-CNI based GVHD-Prophylaxis strategy: Options and Current Clinical use
TBC

Does Gut Microbiome predict infections post transplant
Florent Malard, Paris

10:40 AM- 11:10 AM

Novel insights in biology and treatment of acute GVHD
Takanori Teshima, Sapporo

Treatment of MDR Gram negative infections- molecular basis of treatment
Parikshit Prayag, Pune

11:10 AM- 11:40 AM

Immune Monitoring After Allogeneic Hematopoietic Cell Transplantation:
Toward Practical Guidelines and Standardization
TBC

PTLD- risk factors, preventive strategies and treatment
HsIu- Hao Chang , Taipei

11:40 AM- 12:10 PM

Novel insights in biology and treatment of chronic GVHD
Kenichi Matsuoka, Okayama

Newer insights in treatment of CMV infections
Bor Sheng Ko, Taipei

12:10PM- 1:10 PM

Industry Sponsored Lunch Symposium

01:10 PM-03:10 PM

Session 8 & 9

Oral Presentations

Oral Presentations

03:10 PM- 03:30 PM

BREAK

03:30 PM- 04:30 PM

General Assembly Meeting

04:30 PM -06:30 PM

Session 10 & 11

Cellular Therapies Beyond Transplantation

Post Transplant complications

04:30 PM -05:00 PM

Cellular Therapy for post transplant infections
David Gottlieb,Sydney

Management of non-infective pulmonary complications:- what is new?
TBC

05:00 PM -05:30 PM

Indigenous CAR-T product for B Cell Malignancies
Gaurav Narula,Mumbai

Diagnosis and mangement of poor graft function
Khalid Halahleh, Amman

05:30 PM -06:00 PM

Gene Corrected HSCT- a reality
Dr Alok Srivastava,Vellore

Novel conditioning regimens to decrease regimen related toxicities
TBC

06:00 PM -06:30 PM

Various DLI strategies post transplant to prevent and treat relapse in hematological malignancies
X J Huang , Beijing

TA-TMA- diagnosis, risk factors and treatment
Eleni Gavriilaki, Thessaloniki

7.00 PM Onwards

Industry Sponsored Dinner Symposium

October 9, 2022 (Sunday) – Day 4

09:00 AM -09:40 AM

Plenary Session

Role of Cell-free DNA profiling in hematopoietic cell transplantation

Iwijn De Vlaminck, New York

09:45 AM – 11:45 PM

Session 12 &13

Alternate Donor Transplantation

Oral Presentations

09:45 AM – 10:15 PM

How to select donor for T replete and T deplete haplo transplants
Piyanuch Kongtim, California

10:15 AM – 10:45 PM

Bone marrow or PBSC- does it really matter in T replete haplo transplants
Navneet Majhail, Tennessee

10:45 AM – 11:15 PM

Haplo vs MUD vs Cord in acute leukemia- current status
Ming Yao, Taipei

11:15 AM – 11:45 PM

Is it the end of the road for cord transplant?
Willian Hwang, Singapore

11:45 AM – 12:45 PM

Industry Sponsored Lunch Symposium

12:45 PM- 01:00 PM

Award Announcements and Closing Remarks